Dubai, UAE – May 7, 2025: Endocare, a UAE-based healthcare company pioneering in metabolic health and obesity management, has successfully closed a strategic funding round led by Germany’s RbetaQ Holding, a family office renowned for supporting breakthrough innovations in healthcare and technology.
This funding round marks a major milestone in Endocare’s growth strategy as it accelerates its expansion across the United Arab Emirates and the Kingdom of Saudi Arabia, two of the region’s most dynamic and health-focused markets.
Founded by Leyla Azizova, Janik Schmalhorst, and Hecham Harb, Endocare has established itself as a cutting-edge metabolic health clinic based in Dubai, offering science-driven, integrated care models that combine hormonal therapies with personalized lifestyle interventions.
“The closing of our financing round and the addition of Dr. Ashok Kaul to our board mark pivotal moments in Endocare’s evolution,” said Leyla Azizova, Co-Founder and CEO. “We are thrilled to accelerate our regional expansion and continue providing science-backed, transformative healthcare to a broader audience.”
The lead investor, RbetaQ Holding, brings not only capital but also strategic backing rooted in its long-standing commitment to disruptive healthcare models. With this support, Endocare aims to scale its operations, launch new clinic branches, and expand its specialized services in obesity and metabolic health across the Middle East.
In a move that underscores Endocare’s commitment to technological advancement, the company also welcomed Professor Dr. Ashok Kaul, a renowned expert in data science, AI, and healthcare innovation, to its Board of Directors. Dr. Kaul’s addition is expected to steer Endocare’s digital strategy and enable the integration of AI-powered tools into clinical decision-making and patient experience.
“Endocare’s mission to reshape metabolic healthcare through science and technology aligns perfectly with my vision,” commented Dr. Kaul. “Together, we can drive real change and set new benchmarks for personalized care in the region.”
Endocare’s holistic model is designed to tackle the growing public health challenges linked to obesity, metabolic syndrome, and chronic lifestyle diseases, which are increasingly prevalent in Gulf countries. The clinic’s approach is evidence-based and outcome-focused, empowering individuals to not only lose weight but also improve their quality of life over the long term.
Looking forward, Endocare is investing in AI-enhanced platforms that will optimize treatment protocols, support patient monitoring, and enable customized health plans tailored to each patient’s metabolic profile. These innovations are expected to streamline care pathways and improve outcomes while reducing long-term healthcare costs.
With a strong foundation in Dubai and a clear roadmap for GCC expansion, Endocare is positioning itself as a regional leader in next-generation healthcare, blending clinical excellence with digital innovation to transform how metabolic care is delivered across the Middle East.
